October 7th, 2016
Warning message
This news item is more than a year old. Links, graphics, content, medical information, and statistics may be out of date. We invite you to search, visit our homepage, or contact us to find more current information on the topic you're looking for.Changes to the Saskatchewan Drug Plan coverage of certain medications for Asthma, COPD and Idiopathic Pulmonary Fibrosis
The following changes have been made to the Saskatchewan Formulary regarding the coverage for medications in Saskatchewan effective October 1, 2016. The complete list of changes and criteria for coverage can be found in Bulletin #162.
Recommended as a full Formulary benefit:
- fluticasone furoate, powder for inhalation, 100mcg, 200mcg; brand name Arnuity Ellipta
Used for the treatment of asthma and also used for the treatment of COPD
Recommended as Exception Drug Status benefit (see Bulletin #162 for criteria):
- nintedanib, capsule, 100mg, 150mg; brand name OFEV
Used for the treatment of Idiopathic Pulmonary Fibrosis or IPF
Recommended Additional Exception Drug Status criteria change (see Bulletin #162 for criteria):
- fluticasone furoate/vilanterol, 100ug/25ug; brand name Breo-Ellipta
Used for the long term maintenance treatment of COPD in adults and is also used for the maintenance treatment of asthma in patients 18 years of age and older
Recommended Revised Exception Drug Status criteria (see Bulletin #162 for criteria):
- pirfenidone, capsule, 267mg; brand name Esbriet
Used for the treatment of Idiopathic Pulmonary Fibrosis or IPF